APOBEC3B Upregulation and Genomic Mutation Patterns in Serous Ovarian Carcinoma

Brandon Leonard1,2, Steven N. Hart3, Michael B. Burns1,2, Michael A. Carpenter1,2, Nuri A. Temiz1,2, Anurag Rathore1,2, Rachel I. Vogel1, Jason B. Nikas1, Emily K. Law1,2, William L. Brown1,2, Ying Li3, Yuji Zhang3, Zoya Kingsbury13, John Peden13, Jeremy Chien11, Elizabeth M. Swisher12, Lynn C. Hartmann6, Kimberly R. Kalli10, Ellen L. Goode7, Hugues Sicotte7, Scott H. Kaufmann8,9, and Reuben S. Harris1,2

Matthew J. Maurer3, Ann L. Oberg3, Julie M. Cunningham4, Viji Shridhar5, Debra A. Bell5, Craig April13, David Bentley13, Marina Bibikova13, R. Keira Cheetham13, Jian-Bing Fan13, Russell Grocock13, Sean Humphray13, Kimberly R. Kalli10, Ellen L. Goode7, Hugues Sicotte7, Scott H. Kaufmann8,9, and Reuben S. Harris1,2

Abstract

Ovarian cancer is a clinically and molecularly heterogeneous disease. The driving forces behind this variability are unknown. Here, we report wide variation in the expression of the DNA cytosine deaminase APOBEC3B, with elevated expression in the majority of ovarian cancer cell lines (three SDs above the mean of normal ovarian surface epithelial cells) and high-grade primary ovarian cancers. APOBEC3B is active in the nucleus of several ovarian cancer cell lines and elicits a biochemical preference for deamination of cytosines in 5'–TC dinucleotides. Importantly, examination of whole-genome sequence from 16 ovarian cancers reveals that APOBEC3B expression correlates with total mutation load as well as elevated levels of transversion mutations. In particular, high APOBEC3B expression correlates with C-to-A and C-to-G transversion mutations within 5'–TC dinucleotide motifs in early-stage high-grade serous ovarian cancer genomes, suggesting that APOBEC3B-catalyzed genomic uracil lesions are further processed by downstream DNA 'repair' enzymes including error-prone translesion polymerases. These data identify a potential role for APOBEC3B in serous ovarian cancer genomic instability.


Introduction

Ovarian cancer remains the deadliest gynecologic malignancy in the United States, with an estimated 22,300 new cases and 15,500 deaths in 2012 (1). Although multiple histologic subtypes of ovarian cancer are recognized, including clear cell and endometrioid, the most common and deadly form is serous ovarian cancer. This disease usually escapes detection until it has spread throughout the peritoneal cavity. Previous analyses of high-grade, mostly late-stage serous ovarian cancers have demonstrated mutational inactivation of TP53 in 95% of cases (2). Mutations in several other genes, including BRCA1, BRCA2, and CDK12, also collectively occur in approximately one quarter of high-grade serous ovarian cancers; in addition, genomic instability, as manifested by large amplifications and deletions, is common (2, 3). In contrast, clear cell and endometrioid ovarian cancers are characterized by mutations PIK3CA and ARID1A, with endometrioid ovarian cancers also having frequent CTNNB1 mutations or PTEN loss.

Despite this genetic heterogeneity, ovarian cancers are typically treated with the same chemotherapy after surgical debulking. Most ovarian cancers respond initially to DNA cross-linking chemotherapeutic agents, such as carboplatin (4, 5). However, drug resistance commonly develops, with disease recurrence occurring at an average of 18 months after initiating therapy and only 44% of patients remaining alive 5 years after diagnosis (1). Mechanisms for resistance remain poorly understood, but have been attributed, at least in the case of some BRCA1/2 mutant tumors, to the acquisition of further mutations (6). The mechanisms responsible for the mutational evolution of these cancers are not completely understood.

We recently discovered a major role for enzyme-catalyzed DNA C-to-U deamination in breast cancer (7). The DNA deaminase APOBEC3B was found to be upregulated and active in the...
majority of breast cancer cell lines, and its upregulation in tumors correlated with increased C-to-T transition and overall base substitution mutation loads (7). APOBEC3B is one of seven APOBEC3 deaminases, which have broad and overlapping functions in providing innate immunity to a large number of DNA-based parasites, including retroviruses (with susceptible cDNA intermediates), some DNA viruses, and even naked foreign DNA (ref. 8, and references therein). These APOBEC3 enzymes are related to the antibody-diversification enzyme–activation-induced DNA cytidine deaminase (AID) and the APOB mRNA-editing protein APOBEC1 (9). All nine of these enzymes exhibit DNA deaminase activity in multiple assays. Furthermore, transgenic expression of AID and APOBEC1 can induce tumor formation in mice (10–12). In humans, AID is associated with B-cell tumorogenesis, imatinib resistance, and BCL2 gain-of-function (13–16). However, because human AID and APOBEC1 are expressed predominantly in B lymphocytes and gastrointestinal tissues, respectively, it is unlikely that they contribute to tumorigenesis elsewhere. Based on the fact that breast and ovarian cancers have similar mutation spectra (17) and often show high degrees of genomic instability (2, 18), here we test the possibility that APOBEC3B is an active source of genomic DNA damage and mutagenesis in ovarian cancer.

Materials and Methods

Cell lines

A2780, IGROV-1, OVCAR3, OVCAR5, OVCAR8, OV17, OV167, OV177, OV202, PEO1, PEO4, and SKOV3IP were obtained from the Mayo Clinic ovarian cell line repository. SKOV3, ES2, and TOV-21G were provided by Dr. Martina Bazarro (University of Minnesota, Twin Cities, MN; details of all cell lines in Supplementary Table S1). RNA from IMCC3, 1816–575, 1816, 1816–575, JOSE-VAN, MA148, CAOV3, OVCA29, HEY, and OVCA453 were provided by Dr. Amy Skubitz (University of Minnesota, Twin Cities, MN). Normal fallopian tube epithelial lines were derived by culture of epithelial cells recovered from fimbria (received at the University of Washington for non-neoplastic indications in accordance with the institutional-review-board–approved protocol 08#27077).

APOBEC expression profiling of cell lines

As specific antibodies for APOBEC3B are not yet available, quantitative reverse transcription-PCR (qRT-PCR) was used for mRNA quantification as described previously (7, 19, 20). RNA was isolated using the RNeasy Mini Kit (Qiagen, cat#74106). cDNA was prepared using the Transcriptor Reverse Transcriptase Kit (Roche, cat#03531287001), and qPCR was performed using the Illumina GAIIx with 40× average coverage. Detailed methods used for mutation calling can be found in the Supplementary Materials. In addition, we performed resequencing of TP53 by Sanger sequencing (21) and targeted capture sequencing in a subset of tumors and normal samples (3) to confirm TP53 mutation status and validate a somatic BRCA2 mutation in one tumor that had been identified in whole-genome sequences.

Statistical analyses

Statistically significant differences between normal and tumor tissue, high and low grade, and early and late stage were determined using the Wilcoxon rank sum test. The Wilcoxon signed rank test was used to analyze matched normal and tumor tissues. Association between APOBEC3B expression levels and mutation counts were examined graphically, with significance determined using Spearman correlation coefficients and P-values. Best-fit lines for mutation correlations were estimated using linear regression (Graphpad Prism v.5.0).

Results

APOBEC3B expression and localization in ovarian cancer cell lines

As an initial test for APOBEC3B in ovarian cancer, we used qRT-PCR to survey the mRNA levels of APOBEC3B and all of the
related deaminase family members in a panel of ovarian cancer cell lines (Fig. 1A; Supplementary Fig. S1 and Table S1). The expression level of each deaminase family member was normalized to that of the constitutive housekeeping gene TATA binding protein (TBP). This analysis revealed that APOBEC3B expression varied widely across these cell lines (Fig. 1A). In contrast, immortalized ovarian epithelial lines (OSE) used as controls showed a much narrower range of APOBEC3B expression (Fig. 1A). Ten of 18 [56%; 95% confidence interval (CI): 30.8–78.5%] ovarian cancer cell lines had APOBEC3B mRNA levels more than 3 SDs above the mean of the control, had APOBEC3B levels similar to those found in the OSE lines (Fig. 1A).

Examination of additional deaminase members revealed that mRNA of the most closely related family member, APOBEC3A, was undetectable in 16 out of 18 (88.9%; 95% CI 65.3–98.6%) ovarian cancer cell lines, consistent with its developmental confinement to myeloid lineage cell types (Supplementary Fig. S1; refs. 19, 20). Although some of the other family members were expressed to varying degrees in several of the ovarian cancer cell lines, none were overexpressed in the majority of lines based on the same statistical criteria (3 SDs over the mean level in the five OSE lines; Supplementary Fig. S1).

We next investigated whether APOBEC3B protein localizes to the nuclear compartment in ovarian cancer cell lines, as it does in several other cancer and immortalized cell lines (7, 23–28). Because specific antibodies for APOBEC3B are not yet available, we determined the localization of transfected APOBEC3B-eGFP in live ovarian cancer cells and APOBEC3B-HA in fixed and permeabilized cell lines by fluorescence microscopy. Both APOBEC3B-eGFP and APOBEC3B-HA were predominantly nuclear in the OVCAR5, IGROV-1, and A2780 ovarian cancer cell lines (Fig. 1B). Taken together, these qRT-PCR and localization data suggested that APOBEC3B is positioned to pose a threat to ovarian genomic integrity.

Endogenous APOBEC3B activity in ovarian cancer cell lines

The gold standard for quantifying an endogenous protein is measuring its functional activity. We, therefore, assayed the endogenous DNA C-to-U deaminase activity in three of the highest and lowest APOBEC3B-expressing cell lines using a fluorescence-based assay (Fig. 2A and Supplementary Fig. S2). Clear endogenous DNA deaminase activity was detected from the APOBEC3B-high but not the low-expressing lines, suggesting a direct link. To ask which cellular compartment contained the source of this activity, we generated cytoplasmic and nuclear protein extracts from the APOBEC3B-high lines and assayed the activity of each fraction. High levels of single-stranded DNA C-to-U activity were detected in the nuclear, but not the cytoplasmic, protein fractions, consistent with localization data (Fig. 2B and C). To test whether this nuclear deaminase activity was specifically due to endogenous APOBEC3B, we also performed the experiments using protein extracts prepared from pools of cells transduced with control or APOBEC3B short hairpin RNAs (shRNA). Two independent knockdown constructs were used, with one causing stronger depletion of endogenous APOBEC3B mRNA levels (Fig. 2B, blue vs. green bars; ref. 7). The level of APOBEC3B knockdown correlated directly with loss of nuclear ssDNA C-to-U deaminase activity, with the stronger shRNA causing a larger diminution of activity (Fig. 2C). OVCAR5, IGROV-1, and A2780 yielded similar results.

In parallel, we also assessed the dinucleotide deamination preference of endogenous APOBEC3B in nuclear and cytoplasmic protein extracts from the same cell lines. In all instances, a single-stranded DNA substrate with a 5′-TC deamination target was strongly preferred over other dinucleotide-containing substrates (Fig. 2C and Supplementary Fig. S3). Taken together, these coupled genetic knockdown and
enzymatic activity experiments demonstrate that most, if not all, of the measurable DNA deaminase activity in the nuclear compartment of the tested ovarian cancer cell lines is due to the endogenous APOBEC3B enzyme.

**Deamination kinetics of recombinant APOBEC3B**

Deoxynucleotide identities immediately 5' and 3' of target DNA cytosines can strongly influence the efficiency of DNA deamination by APOBEC3 family members (7, 29–31). Therefore, to compare the cell-based studies (discussed earlier) with mutational data from clinical samples (discussed later), we determined the local sequence specificity and enzyme kinetics of recombinant APOBEC3B in vitro. Using the catalytic domain of APOBEC3B (residues 195–382) purified from HEK293 cells, we conducted a series of time-course experiments with substrates spanning all 16 permutations of deoxynucleotides immediately 5' and 3' of the target cytosine (i.e., 5'-NCN). Quantification of deamination products accumulating over time enabled catalytic efficiencies to be determined. These analyses revealed that the nucleotide directly 5' of the target cytosine was a stronger determinant of APOBEC3B deamination than the 3' nucleotide. More specifically, we found that 5'-TC dinucleotides support the highest reaction rates, and 5'-AC and 5'-GC support the lowest (representative gels in Fig. 3A and quantification in Fig. 3B). Overall, these in vitro preferences of recombinant APOBEC3B catalytic domain confirmed and extended our previous studies (7, 32), and they correlated strongly with and further validated results obtained with the full-length endogenous enzyme in nuclear extracts of breast (7) and ovarian cancer cell lines (this study, discussed in earlier sections). Importantly, these substrate preferences, which represent the intrinsic deamination activity of APOBEC3B, provided a hierarchy of "signatures" for comparison with the mutation patterns in ovarian cancer genomic mutation datasets described further.

**APOBEC3B expression in ovarian tumors**

To extend our studies to clinical ovarian cancer specimens, we initially assayed DNA deaminase family member mRNA expression in eight normal or benign ovarian tissues (Supplementary Table S3) and a series of 23 ovarian cancers, including 16 early-stage high-grade serous ovarian cancers that were also subjected to whole-genome sequencing (clinical characteristics in Supplementary Tables S4 and S5). High-quality RNA was prepared from flash-frozen tissues, and each of the deaminase family members were quantified by qRT-PCR as described earlier. As expected based on our cell line expression analysis, APOBEC3B mRNA varied widely in ovarian cancers, but was significantly upregulated in comparison with normal ovarian tissue as a control (tumor n = 23 vs. normal tissue n = 8; P = 0.011 by the Wilcoxon rank sum test; Supplementary Fig. S4). In addition, APOBEC1 was upregulated in one tumor (P = 0.006), but this was considered a rare exception because it was not supported by cell line or additional tumor data. No significant differential expression was apparent for APOBEC2 (P = 0.541), APOBEC3G (P = 0.668), APOBEC3H (P = 0.214), AID (P = 0.214), or APOBEC4 (0.107). Interestingly, lower levels were found in the tumor than in normal ovaries for APOBEC3C (P = 0.002), APOBEC3D (P = 0.002), APOBEC3F (P = 0.040), and APOBEC2 (P = 0.003), suggesting either that these family members are downregulated in ovarian cancers or they are poorly expressed in cells that eventually develop into tumors (Supplementary Fig. S4).

Using the same qRT-PCR assay and the data from our initial cohort, we next examined APOBEC3B expression in an expanded panel of 77 ovarian tumors (clinical characteristics in...
Figure 3. Intrinsic DNA deamination preferences of recombinant APOBEC3B. A, representative gel images of APOBEC3B catalytic domain DNA deamination products accumulating over the indicated reaction times for the 5'-TCA (most preferred) and 5'-GCA (least preferred) trinucleotide contexts. Complete deamination by APOBEC3A is shown as a positive control (Con). B, APOBEC3B catalytic domain deamination kinetics using 5'-TCA, CCN, GCN, and ACN single-stranded DNA substrates (n = 16 reaction conditions done each in triplicate; mean values are shown with SD smaller than symbols in all but one instance). Reactions with 5'-RCN substrates had indistinguishably low activity (R = A or G).

Supplementary Tables S4 and S5), and determined whether higher APOBEC3B correlates with stage and/or grade (Fig. 4A–D). APOBEC3B mRNA levels in most normal ovarian tissues were only a small fraction of those of the housekeeping gene TBP with an average of 0.07 ± 0.04 APOBEC3B/TBP (n = 20, excluding OV412 as an outlier; Dixon Q test confidence limit, 99%). Using a strict cutoff of 3 SD above the normal ovariary tissue mean, we found that 44 of the 66 ovarian carcinomas without matched normal samples show upregulated APOBEC3B mRNA levels (66.7%; 95% CI, 53.7–78.1%; Fig. 4A). In addition, APOBEC3B was upregulated in nine of 11 instances where both matched normal and tumor tissue was available (P = 0.010 by Signed rank test; Fig. 4B). When comparing all 77 tumors, there was no statistical difference in APOBEC3B mRNA levels in late versus early-stage samples (P = 0.222 by Wilcoxon rank sum test; Fig. 4C), suggesting that APOBEC3B upregulation may occur early in ovarian cancer development. In contrast, there was a significant difference between grade 3 and all lower grade samples (P = 0.044 by the Wilcoxon rank sum test; Fig. 4D), suggesting that APOBEC3B may contribute to tumor dedifferentiation.

As in many cell-of-origin versus tumor comparisons, ovarian or fallopian tube epithelia comprise a small fraction of the tissue, while tumors are mostly epithelial. This factor is further affected by microenvironment changes that occur during tumor development. These and other factors complicate direct comparisons between normal tissues and tumor samples. Therefore, to fortify these comparisons, we performed an additional analysis using the mean APOBEC3B expression values from immortalized OSE lines (Fig. 1A) and expression values from the tumors described here (Fig. 4A). Similar to the analysis described earlier, APOBEC3B expression levels were at least 3 SD above the mean of the immortalized OSE cells in 12 of the 77 ovarian tumors. Therefore, regardless of the normal samples used for comparison, a subset of ovarian tumors show upregulated APOBEC3B expression levels.

Next, The Cancer Genome Atlas (TCGA) Network microarray and RNA sequencing (RNAseq) data were used to test the robustness of our qRT-PCR approach and to extend expression results to larger, independent datasets (Fig. 4E and F). TCGA microarray data were available for 581 ovarian cancers and eight unrelated normal ovarian tissues, and an analysis of these data indicated APOBEC3A and APOBEC3B upregulation in malignant tissues (P < 0.0003 by Mann–Whitney U test; Fig. 4E and Supplementary Table S6). However, the microarray result for APOBEC3A is likely a false-positive because five out of 11 APOBEC3A probes have more than 22/25 nucleotides of identity with APOBEC3B, and eight out of 11 APOBEC3B probes have more than 22/25 nucleotides of identity with APOBEC3A (7). Moreover, modest APOBEC3G downregulation is also a false positive because the probe set in question has no complementarity to APOBEC3G, and the second APOBEC3G probe set showed no significant difference. RNAseq data largely overcome these technical limitations because the longer paired-end reads enhance the chance of spanning a region of heterology and enabling the correct gene-specific assignment of sequence reads (7, 32). Analysis of the RNAseq data available on 188 TCGA samples demonstrated that the expression of APOBEC3A is lower than APOBEC3B in high-grade, late-stage serous ovarian cancer specimens, confirming that the APOBEC3A measurement on the microarray is likely a false positive (Supplementary Fig. S5). Moreover, quantification of APOBEC3B expression by RNAseq across the entire 188 TCGA ovarian cancer samples examined by this technique also yielded data that largely mirrored our qRT-PCR results (Fig. 4F). In addition, a subset of the samples analyzed by qRT-PCR was part of the TCGA studies (n = 42; denoted by asterisks in Fig. 4A and indicated in Supplementary Table S5). Analysis of the 32 TCGA samples analyzed by both qRT-PCR and RNAseq revealed a strong correlation between results obtained with both techniques (P < 0.0001, r = 0.88 by the Spearman correlation; Fig. 4G). This concordance lends confidence to the overall datasets, and fortifies the conclusion that APOBEC3B expression varies widely but appears to be elevated in many of the ovarian cancers studied relative to normal ovarian tissues or immortalized OSE samples used as controls in this study.

Mutation patterns in early-stage ovarian tumors

To gain further insight into the biologic consequences of varied APOBEC3B expression in ovarian cancer, we analyzed whole-genome sequences from 16 early-stage, mostly high-grade serous ovarian cancers (Supplementary Table S4) and
Figure 4. APOBEC3B expression in ovarian tumors. A, APOBEC3B levels in the indicated normal (green triangles; n = 21) and unmatched cancerous (red circles; n = 66) ovarian tissues. Cancer history is indicated by open (no history) or filled green symbols (some history; see Supplementary Tables S2 and S4 for additional patient information). Tumor stage is indicated by open (early-stage) or closed (late-stage) red symbols. Data points in each category are arranged from lowest to highest APOBEC3B expression level. Each point reports the mean APOBEC3B level of 3 independent qRT-PCR reactions presented relative to mRNA levels of the constitutive housekeeping gene TBP (error bars = 1 SD). Asterisks indicate samples that are also in TCGA data sets with the alternative identifiers listed in Supplementary Table S5. B, dot plot showing APOBEC3B expression in matched normal and tumor specimens (n = 11 unrelated to specimens in A). Lines connect matched specimens. P values were calculated using the Signed rank test. C and D, dot plots showing the relationship between APOBEC3B levels (as in A) and tumor stage (early vs. late) or tumor grade (low vs. high). P values were calculated using the Wilcoxon rank sum test. E, relative microarray APOBEC3 expression levels based on data from the indicated probe sets. A false-positive APOBEC3A signal is expected due to high nucleotide identity with APOBEC3B and cross-hybridizing probe sets (see supplement to ref. 7). F, APOBEC3B quantification by RNA sequencing of 188 TCGA ovarian tumors. APOBEC3B mRNA levels are presented relative to those of the housekeeping gene TBP and plotted from lowest to highest. No normal tissues were available for comparison. G, a two-dimensional plot comparing qRT-PCR and RNA sequencing data for tumor samples common to each analysis (n = 32). P values calculated using the Spearman correlation.
examined the relationship between APOBEC3B expression and the mutations found in these cancers. Importantly, all patients were treatment naïve and had no evidence of other cancers prior to diagnosis. The total load of somatic mutations varied widely among the 16 early-stage serous ovarian cancers, with a range from 1,055 to 8,249 mutations per specimen (Supplementary Table S4). A significant positive correlation ($P = 0.013, r = 0.60$ by the Spearman correlation) was observed between mutation load and APOBEC3B levels (Fig. 5A). Approximately 60% of base substitutions occurred at C/G base pairs, which is notable given the A/T richness of the human genome.

Surprisingly, we found that the majority of mutations occurring at C/G base pairs in ovarian cancer are C-to-A or C-to-G transversions (Fig. 5B). Moreover, these transversions correlated with APOBEC3B expression levels (Fig. 5C). This finding was unexpected because the anticipated simplest outcome of a C-to-U genomic DNA lesion is a C-to-T transition through DNA replication or misrepair, as observed for breast cancer (see Discussion). Nevertheless, this transversion pattern is most likely due to the APOBEC3B enzymatic activity, as these events most frequently occurred within APOBEC3B-preferred 5'-TC motifs (Fig. 5D). The rarity of transversion mutation events at 5'-TCG sites may be due to a natural scarcity of CpG dinucleotides in the human genome (in comparison to other dinucleotides) and/or to the lower activity of APOBEC3B on 5'-methyl-cytosine substrates in comparison with nonmethylated cytosines (by analogy to the closely related enzyme APOBEC3A; refs. 33, 34).

Figure 5. Ovarian cancer genomic mutation patterns. A, correlation between APOBEC3B expression and total mutation loads in whole-genome sequences of 16 early-stage serous ovarian carcinomas (Supplementary Table S4) assessed using the Spearman correlation. B, grouped analysis of whole-genome mutation types in all 16 cancers. C, correlation between APOBEC3B expression levels and mutation type at C/G base pairs in whole-genome sequences assessed using the Spearman correlation. D, trinucleotide context of the mutated C for transversions (top) and transitions (bottom) in whole-genome sequences (16,986 transversions and 13,232 transitions). E-H, as above for A-D, except these analyses were done using RNAseq-confirmed mutations from the same 16 early-stage serous ovarian carcinomas (1,468 transversions and 1,198 transitions).
A unique finding here is the significant correlation between APOBEC3B expression levels, *in vitro* APOBEC3B deamination preferences, and the cytosine transversion signatures in early-stage ovarian cancers. In breast cancer, we recently reported a correlation between endogenous APOBEC3B expression and transition mutations at C/G base pairs, which can be easily explained by replication past uracil lesions (Fig. 6B; ref. 7). Concordant results were observed when APOBEC3B was overexpressed exogenously in HEK293 cells (7, 35). In contrast, the C-to-A and C-to-G transversions that predominate here are more complicated outcomes of an initiating genomic C-to-U lesion. The presence of these mutational events in ovarian cancer strongly suggests a model in which genomic uracils are converted by uracil DNA glycosylase into abasic sites, which in turn become substrates for error-prone translesion DNA synthesis (TLS; Fig. 6D). Several translesion DNA polymerases are strong candidates for such a role in generating transversion mutations downstream of cytosine deamination, including REV1, which elicits a strong preference for pyrimidine insertion opposite an abasic lesion (36). Indeed, such a model is supported by recent studies in yeast, which showed that both UNG and REV1 proteins are required for heterologous expression of human AID/APOBEC3 proteins to cause transversion mutations (37). Somatic hypermutation of immunoglobulin gene variable regions initiated by AID-dependent C-to-U deamination events also provides precedent that

Discussion

In this study, we have shown that APOBEC3B expression levels vary widely in ovarian cancer cell lines and clinical samples and are, in a substantial proportion of samples, higher than those in OSE lines, fallopian tube epithelial (FTE) cultures, or normal ovarian tissues. Knockdown experiments established that APOBEC3B was the only detectable source of DNA cytosine deaminase activity in nuclear extracts from multiple ovarian cancer cell lines. Microscopic images showed that epitope-tagged APOBEC3B is predominantly nuclear, in full agreement with the subcellular fractionation and activity studies of endogenous APOBEC3B. Biochemical experiments revealed the intrinsic cytosine deamination preferences for the catalytic domain of APOBEC3B and, interestingly, the preferred motif, 5'-TC, corresponds to the most abundant sites of C-to-A or C-to-G transversion mutations observed in whole-genome sequencing of early-stage serous ovarian cancer genomic DNA. Importantly, APOBEC3B expression levels correlated with mutational load in these tumors, suggesting a potential role for this enzyme in generating mutagenic lesions in ovarian cancer.

www.aacrjournals.org Cancer Res; 73(24) December 15, 2013 7229

Published OnlineFirst October 23, 2013; DOI: 10.1158/0008-5472.CAN-13-1753

Published April 15, 2017. © 2013 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from cancerres.aacrjournals.org on April 15, 2017.
enzyme-catalyzed uracil lesions can result in all six types of base substitutions (14, 38). In particular, in mouse models, the AID-induced C-to-A and C-to-G events are largely dependent upon the uracil excision enzyme UNG2 and most likely involve translesion synthesis polymerases (14, 38).

The transversions observed here in early-stage ovarian cancers in an APOBEC3B-preferred dinucleotide context raises many additional questions for future studies, including identifying the causal TLS polymerase (because humans have many more than yeast), explaining the differential processing of APOBEC3B-dependent lesions in different tumor types (e.g., breast vs. ovary), and addressing whether other mutagenetic outcomes may also be APOBEC3B-dependent. For instance, incomplete repair of even a single uracil lesion can lead to a nicked DNA strand and, together with DNA replication (or even local synthesis), result in double-strand breaks that, in turn, are known to precipitate larger scale chromosomal aberrations such as insertions, deletions, duplications, and translocations (Fig. 6E). Thus, the elevated APOBEC3B expression documented here might also contribute to some of the larger-scale genomic alterations that are characteristic of many advanced serous ovarian tumors (2). Another critical point to address in future studies is assessing the effect of APOBEC3B expression on clinical outcomes, such as overall and progression-free survival, response to therapy, and rate of recurrence. To do this, large cohorts of clinical specimens with well-documented patient histories will need to be examined.

Recently, three separate analyses of large data collections examined the relationship between mutation pattern, mutation load, and APOBEC expression across multiple tumor types, including ovarian cancer (32, 39, 40). Although these analyses showed evidence for APOBEC-driven mutagenesis in multiple tumor types, none focused on ovarian cancer. This may be due to the fact that ovarian cancer has more modest APOBEC3B expression levels and mutation loads in comparison with some of these other cancers. The present study is the first to focus on ovarian cancer and differs from these recent reports in many ways: (i) we used specific qRT-PCR assays to profile APOBEC3B in ovarian cancer cell lines and tissues; (ii) we performed experiments to show that APOBEC3B is active in the nuclear compartment of ovarian cancer cell lines; (iii) we studied the relationship between APOBEC3B expression and mutation burden among individual ovarian cancers rather than across tumor types; and (iv) we examined mutation burden using newly available early-stage ovarian cancer whole-genome sequences. The results shown here suggest that these earlier studies may have been limited by both the specificity of the techniques used to measure gene expression and the limitations of exomic as opposed to whole-genome sequencing. Moreover, our work emphasizes the importance of in-depth studies of specific tumor types that may be overlooked by global analyses.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Writing, review, and/or revision of the manuscript: B. Leonard, S.N. Hart, R.I. Vogel, J.B. Nikas, A.L. Oberg, J.M. Cunningham, V. Shridhar, J. Chien, E.M. Swisher, K.R. Kalli, H. Sicotte, S.H. Kaufmann, R.S. Harris
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): B. Leonard, A. Rathore, J.B. Nikas, W.L. Brown, R.K. Cheetham, J. Peden, L.C. Hartmann
Study supervision: B. Leonard, L.C. Hartmann, S.H. Kaufmann, R.S. Harris
Other (All research of microarray databases and bioinformatic analysis of all microarray data): J.B. Nikas

Acknowledgments
The authors thank M. Bazarro for cell lines, A. Skubitz for cell line RNA, P. Schneider for isolating tumor RNA, and several laboratory members for helpful discussions.

Grant Support
The work in the Harris laboratory was financially supported in part by seed grants from the Minnesota Ovarian Cancer Alliance and the University of Minnesota Clinical and Translational Science Institute (supported by NIH grant no. 1UL1RR03183). R.I. Vogel, N.A. Temiz, and J.B. Nikas were supported by NIH P30 CA177598 utilizing the Biostatistics and Bioinformatics Core shared resource of the Masonic Cancer Center, University of Minnesota. M.B. Burns was supported by a Department of Defense Breast Cancer Research Program Predoctoral Fellowship (BC101124). M.A. Carpenter was supported by NIH F32 GM095219. The work of the Mayo Clinic Ovarian Cancer Research Program was supported by NIH P50 CA136393, NIH P30 CA15083, R01 CA124451, an Ovarian Cancer Research Fund Program Project Development Grant, and a grant from the Fred C. and Katherine B. Andersen Foundation. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received June 25, 2013; revised September 4, 2013; accepted September 21, 2013; published OnlineFirst October 23, 2013.

References


